Bio-pharma industry, albeit slow in adopting digital intervention, is now opening up to new-age automation technologies, Kaushik told Financial Express.com.
The acquisition of biosimilars assets of Viatris significantly strengthens BBL’s position in providing affordable access to patients through its portfolio…
